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Abstract
Background: Recent studies of CH-C patients have demonstrated a strong association between IL28B CC
genotype and sustained virologic response (SVR) after PEG-IFN/RBV treatment. We aimed to assess whether IL28B
alleles rs12979860 genotype influences gene expression in response to PEG-IFN/RBV in CH-C patients.
Methods: Clinical data and gene expression data were available for 56 patients treated with PEG-IFN/RBV. Whole
blood was used to determine IL28B genotypes. Differential expression of 153 human genes was assessed for each
treatment time point (Days: 0, 1, 7, 28, 56) and was correlated with IL28B genotype (IL28B C/C or non-C/C) over
the course of the PEG-IFN/RBV treatment. Genes with statistically significant changes in their expression at each
time point were used as an input for pathway analysis using KEGG Pathway Painter (KPP). Pathways were ranked
based on number of gene involved separately per each study cohort.
Results: The most striking difference between the response patterns of patients with IL28B C/C and T* genotypes
during treatment, across all pathways, is a sustained pattern of treatment-induced gene expression in patients
carrying IL28B C/C. In the case of IL28B T* genotype, pre-activation of genes, the lack of sustained pattern of gene
expression or a combination of both were observed. This observation could potentially provide an explanation for
the lower rate of SVR observed in these patients. Additionally, when the lists of IL28B genotype-specific genes
which were differentially expressed in patients without SVR were compared at their baseline, IRF2 and SOCS1
genes were down-regulated regardless of patients’ IL28B genotype. Furthermore, our data suggest that CH-C
patients who do not have the SOCS1 gene silenced have a better chance of achieving SVR. Our observations
suggest that the action of SOCS1 is independent of IL28B genotype.
Conclusions: IL28B CC genotype patients with CH-C show a sustained treatment-induced gene expression profile
which is not seen in non-CC genotype patients. Silencing of SOCS1 is a negative and independent predictor of
SVR. These data may provide some mechanistic explanation for higher rate of SVR in IL28B CC patients who are
treated with PEG-IFN/RBV.
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The most common cause of chronic liver disease,
chronic hepatitis C virus (CH-C), affects approximately
170 million people worldwide [1]. Until recently, treat-
ment of CH-C included a combination of pegylated
interferon-a (PEG-IFN-a) and ribavirin (RBV). This
treatment typically led to sustained virologic response
(SVR) rates of 47% to 54% for previously untreated
patients [2,3]. Subsequent studies have clarified that the
success of this treatment is affected by several host,
viral, and treatment factors. Host factors that can influ-
ence SVR include obesity, presence of cirrhosis, ethni-
city, gender, and age [4-7]. Recently, a landmark
genome wide association study of about 1,600 CH-C
patients has identified a single nucleotide polymorphism
(SNP) on chromosome 19q13, rs12979860 which was
strongly associated with SVR [8]. This SNP is located
upstream of the IL28B gene, encoding for IFN-l3. Sub-
sequently, the C/C genotype of IL28B was shown to be
associated with a greater than 2 fold increase in SVR as
compared with the C/T and T/T genotypes [8]. In addi-
tion, a subsequent study provided evidence for strong
association of the C/C genotype with the spontaneous
resolution of HCV infection [9]. Since these landmark
studies, numerous lines of evidence have solidified the
association between the IL28B C/C genotype and SVR
in patients with CH-C. Although initially the association
of IL28B C/C genotype with spontaneous clearance and
SVR were noted in patients with HCV genotype 1
[10,11], more recent data have suggested a similar
impact for IL28B on other HCV genotypes [12-15].
Despite the great strides in solidifying the association
between IL28B genotypes and SVR, the exact underlying
mechanism remains largely unknown [16-18]. In an
attempt to shed some light on the potential mechanism
of the allelic association of IL28B with SVR, we assessed
differential gene expression in CH-C patients according
to their IL28B genotypes over the course of the PEG-
IFN/RBV treatment.
Methods
The study used existing specimen repository for IL28B
genotyping as well as our previously reported gene
expression and associated clinical data [19]. We selected
CH-C patients treated with a course of the standard
doses of PEG-IFN-a2a or PEG-IFN-a2b and a weight-
based dose of RBV with the duration of treatment based
on HCV genotypes (N = 56). Of these 56 patients, 28
were treatment naïve and 28 were previously treated).
Clinical, demographic, and laboratory data, as well as
blood samples were obtained prior to treatment and dur-
ing treatment. Blood samples were used for DNA and
mRNA extraction as described below.
During treatment, early virologic response (EVR, as
defined by > 2 log drop by week 12) and complete viro-
logic response (complete EVR, as defined by undetect-
able virus by week 12) as well as post treatment
sustained virologic response (SVR) rates were deter-
mined for each patient.
Ethical approval
This study is in compliance with the Helsinki Declara-
tion and was approved by the Inova Health Systems
Institutional Review Board. Written informed consent
was obtained from the participants of this study.
DNA Extraction and Genotyping
Frozen whole blood was used for IL28B genotyping after
genomic DNA extraction using QIAamp DNA Blood Mini
kit (Qiagen). IL28B genotyping was performed by tetra-
primer refractory mutation system PCR as described by
Galmozzi et al [20]. The primers sequences were as fol-
l o w s :o u t e rF w :5 ’ AACTCAACGCCTCTTCCTCCT 3’;
outer Rv: 5’ TTCCCATACACCCGTTCCTGT 3’;i n n e r
Fw (T): 5’ AGGAGCTCCCCGAAGGAGT 3’;i n n e rR v
(G): 5’ GTGCCATTCAACCCTGGTACG 3’. For each
sample, we used 20-60 ng of genomic DNA for PCR (Hot-
StarTaq Master Mix Kit; Qiagen) in test tubes containing
20 pmol of each of the four primers to amplify both the
“C” and “T” alleles. Genotypes were discriminated by size
via standard electrophoresis.
RNA Extraction and Gene Expression Profiling
As previously reported [19], blood samples for each
patient were collected into PAXgene™ RNA blood
tubes (PreAnalytiX) prior to treatment (day 0), 1 day
(day 1), 1 week (day 7), 4 weeks (day 28), and 8 weeks
(day 56) after the first dosing. From the pre-treatment
as well as post treatment PBMCs, total RNA was
extracted, quantified and used for one step RT-PCR to
profile the expression of 153 human genes that belong
to various IFN-inducible and immune response related
pathways. Amplification was performed with SYBR
®
Green using 5 ng of total RNA as a template in 384-
well format with a duplicate of each 15-μl reaction
using Prism
® 7900HT Sequence Detection System
(Applied Biosystems). mRNA expression levels were
normalized by using six housekeeping genes, a reference
RNA and the ΔΔCt method [21].
Statistical Analysis
For each time point (day 0, 1, 7, 28 and 56), differen-
tially expressed genes were separated into up and down-
regulated gene lists according to the IL28B C/C or non-
C/C (T/T or T/C) genotypes. Additionally, for each time
point, gene expression data were also correlated with
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expression levels for each gene were calculated. Differ-
entially expressed genes were determined using the
Mann-Whitney test (p-value < 0.05) for the expression
levels of each gene quantified during each of the five
visits.
Pathway Specific Analysis and Mapping
Pathways specific analyses were performed using the
KEGG Pathway Painter (KPP), a novel publicly avail-
able tool (http://www.cos.gmu.edu/~gmanyam/kegg/
index.html). KPP is capable of performing real-time
batch painting of all relevant KEGG pathways accord-
ing to differentially expressed gene lists provided by
the user and placing these genes within molecular
pathways previously described in Kyoto Encyclopedia
of Genes and Genomes (KEGG). For each time point
(day 0-day 56), the pathways encompassing SVR
related genes according to IL28B SNP genotype (C/C
or T*) were sorted in accordance with the pathway
relevance scores, defined as the number of genes high-
l i g h t e db yt h eg e n ee x p r e s s i o ns t u d ya n dd i v i d e db y
the total number of genes within a given pathway. All
pathways shared between two or more SVR related
genes according to IL28B SNP genotype specific com-
parisons were automatically painted according to the
direction of the gene expression change (activation or
suppression). Additionally, pathways relevant to HCV
pathogenesis were selected according to the previously
published studies [22,23]. In order to generate a time
course image of pathway involvement for SVR related
genes according to IL28B SNP genotype, pathways
with the highest scores were organized according to
relevance scores and time course.
Results
Patient Population
Fifty-six patients with CH-C were included in this study.
The baseline characteristics and treatment response to
combination therapy are listed in Table 1.
Of the study cohort, 41% (23/56) had IL28B CC geno-
type and 59% (33/56) had non-CC genotype (TC/TT or
T*) genotypes. In CH-C patients with IL28B C/C geno-
type, 65% (15/23) achieved SVR as compared to 24% (8/
33) in CH-C patients with IL28B T* genotype (p < 0.05).
Restricting the analysis only to HCV genotype 1
patients (43/65), the association of IL28B genotypes
with SVR remained unchanged (SVR: IL28B C/C: 62.5%,
IL28B T*: 22.2%, p < 0.05).
IL28B T* genotype was more prevalent in African
Americans with CH-C (p < 0.05) as compared to all
other ethnic groups. Cirrhosis and female gender were
negatively associated with SVR only in the IL28B C/C
cohort (p < 0.0085 and p < 0.0037, respectively).
Gene Expression Profiling
A total of 150 human genes analyzed in individual qRT-
PCR assays were profiled across five time points (Day 0;
Day1; Day7; Day28; Day56) along the PEG-IFN/RVB
treatment. The complete list of analyzed genes could be
found in the Additional File 1. Gene expression profiles
were used to compare IL28B C/C and IL28B T*cohorts
across all time points for the duration of treatment. For
each of the time points, the genes were separated into up
and down regulated groups according to the genotype.
Additionally, for each time point, genotype-specific
groups of up- and down-regulated genes which were
associated with SVR were identified (Table 2). After the
parsing of the data, gene lists were entered into KPP for
Table 1 Characteristics of the patients with IL28B C/C and IL28B T* genotypes.
Characteristics IL28B C/C IL28B T* All HCV patients
Number of Patients 23 33 56
Sex-Female 6 (26.1%) 15 (45.5%) 21 (37.5%)
Age 49.9 ± 4.4 47.5 ± 6.7 48.52 ± 5.96
Race, African American (#) 1 (4.3%) 8 (24.2%) 9 (16.1%)
Cirrhosis 5(22.7%) 8(25.0%) 13 (24.1%)
Obesity 13(56.5%) 16(48.5%) 29(51.8%)
Diabetes mellitus 1(4.3%) 5(15.2%) 6(10.7%)
HCV genotype 1 16 (65.2%) 27 (81.8%) 43(76.8%)
Pretreatment ALT 96 ± 59 111 ± 79 104 ± 72
Pretreatment HCV RNA (IU/mL) 5,596,354 ± 6,524,048 4,424,606 ± 5,295,969 4,893,305 ± 5,788,661
High Viral Load (> 850,000 IU/mL) 17 (77.3%) 25 (75.8%) 42 (76.4%)
No Complete EVR (p < 4.27 e
-05) 3 (13%) 22 (68.8%) 25 (45.5%)
No EVR (p < 0.005) 1 (4.3%) 12 (37.5%) 13 (26.3%)
Sustained Virologic Response (p < 0.0022) 15 (65.2%) 8 (24.2%) 23 (41.1%)
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patients with HCV genotype 1 only.
Analysis of the Pathways Associated with SVR across Both
IL28B genotypes
The KPP analysis of genes associated with SVR in both
IL28B CC and IL28T* cohorts highlighted several pathways
that may play an important role in determining patients’
response to interferon-based treatment. These pathways
were independently identified for all HCV genotypes as
well as specifically for HCV genotype 1 sub-cohort.
When IL28B C/C and IL28B T* genotypes were
compared to each other, the variation between genes
grouped in “Hepatitis C infection” pathway was the
most striking pathway. This pathway was not only pre-
activated in the IL28B T* patients, but it was also asso-
ciated with a distinct pattern of activation and sup-
pression as compared to the IL28B C/C genotype
(Table 3).
When the lists of genes highlighted in IL28B C/C vs. T*
comparisons were cross-referenced with the list of SVR-
related genes that has been previously reported [20], the
sustained pattern of treatment-induced gene expression
changes during the entire treatment period was observed
only in the IL28B CC patients. On the other hand, in the
T* cohorts, the pre-activation of SVR associated genes
was observed. More specifically, gene expression changes
in the Hepatitis C Pathway (Figure 1) were detected in
patients with IL28B C/C genotype after a week of treat-
ment. Genes associated with this pathway continued to
be differentially expressed at 28 days and 56 days after
treatment was initiated. Although, in CH-C patients with
IL28B T*, genes associated with this pathway were
already activated prior to treatment (Day 0) as well as
early (24 hours) after treatment, this pathway became
less pronounced after treatment (Figure 1, Table 3).
Additionally, we identified two other pathways that
could potentially differentiate IL28B C/C from T* geno-
types in terms of antiviral response. These pathways
were the Measles Pathway (Figure 2) and Chemokine
Signaling Pathway (Table 4).
Analysis of the Pathways Associated with Treatment-
failure Across Both IL28B Genotypes
The lists of genes differentially expressed in CH-C
patients who did not achieve SVR despite having IL28B
C/C genotype (8/23) was compared to IL28B T* geno-
type patients (25/33) who also did not achieve SVR
Table 2 Genes differentially up- or downregulated in SVR in IL28B CC and IL28T* cohorts over the course of the
treatment period (P < 0.05).
Alelle Day 0 Day 1 Day 7 Day 28 Day 56
Up Down Up Down Up Down Up Down Up Down
IL28B CC None ATP6V0B BST2
IL1B
IRF2
NFKB2
PRDM1
SOCS1
CCL4
IFITM1
SSBP1
LIPA
PRKRA
ADAR
ATP6V0B
BTG1
CCL3
CCL4
CREB1
ICAM1
IKBKG
IRF1
LYN
PLAUR
PRKRIR
RNASEL
SOCS1
STAT3
STAT6
TAP2
FYN
IRF3
EIF2AK2
FAS
GBP1
GTPBP2
IFI35
IFI44
IFI44L
IFIT1
IFIT2
IFIT5
IFITM3
IRF7
SELL
SP110
TAP2
TRIM34
DHX9
FYN
IRF3
LIPA
IFITM3 CD81
FYN
IKBKB
IRF3
MX1
PSME2
TRIM14
TRIM26
TRIM34
IL28B T* AIM2
IKBKE
IRF2
LCK
SOCS1
STAT6 IRF2
LCK
TRAF6
NMI
YARS
BTG1
CREB1
FAS
GMPR
HIF1A
IFNAR1
IRF2
SELL
SOCS1
TAP1
TGFB1
TRADD
TRAF6
IL10
SHFM1
YARS
IFNAR1 NMI
PRKRA
CREB1 CTLA4
IFI30
IRF5
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IRF2 and SOCS1 genes were independently down-regu-
lated in both groups of IL28B patients. Although these
CH-C patients had different IL28 B genotypes, they all
shared the common characteristic of not achieving SVR
and having pre-treatment down-regulation of the IRF2
and SOCS1 genes. Neither SOCS1, nor IRF2 expression
levels were different when IL28B C/C genotype and
IL28B T* genotype cohorts were compared. The time
course of the changes in SOCS1 and IRF2 expression
levels in patients who subsequently achieved or not
achieved SVR is shown at Figures 3 and 4, respectively.
Discussion
Although the recent approval of Direct Antiviral Agents
(DAA) for treatment of CH-C will change the treatment
course of CH-C patients, over the past decade, the com-
bination of PEG-INF/RBV has been the standard treat-
ment for CH-C with 47% to 54% SVR rates [24].
Recently, the discovery of IL28B, as a strong predictor
of SVR, has brought a great deal of enthusiasm. Multiple
studies have shown that CH-C patients carrying the C/C
genotype have a two-fold greater chance of SVR than
patients with the T* genotype (8, 10, 11). Our results
are consistent with these data, showing that SVR rates
Table 3 Hepatitis C pathway related genes are
differentially regulated in IL28B CC and IL28 T*
genotypes over the course of the treatment.
Genotype Day 0 Day 1 Day 7 Day 28 Day 56
IL28B CC (0) (0) (5)
RNASEL
IRF3
IKBKG
IRF1
STAT3
(3)
IRF3
EIF2AK2 (PKR)
IFIT1
(3)
CD81
IRF3
IKBKB
IL28B T* (1)
IKBKE
(1)
TRAF6
(3)
TRAF6
IFNAR1
TRADD
(1)
IFNAR1
(0)
Upregulated genes are shown in bold; Downregulated genes are shown in
regular font.
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Figure 1 A map of HCV pathway. Genes differentially activated during PEG-IFN/RBV treatment in patients with IL28B T* genotype are
highlighted in green and with IL28B CC genotype are highlighted in blue.
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Page 5 of 10are 2-3 times higher in CH-C patients with IL28B CC
genotype.
Additional research has shown that IL28B T* genotype
is more common in African American patients with
CH-C [8,9] who typically don’tr e s p o n df a v o r a b l yt o
PEG-IFN/RBV [25]. Consistent with these data, our
study showed a higher prevalence of the T* allele in
African American patients with CH-C (Table 1). These
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provide evidence for validation of our data [26,27].
Despite the strong association between IL28B CC gen-
otype and SVR, the underlying mechanism of IL28 B in
determining SVR remains unknown. It is postulated that
interferon lambda may produce a better immunologic
profile that could favor viral clearance [28]. Recent
s t u d yb yH o n d aa n dc o - a u t h o r sd e m o n s t r a t e dt h a tt h e
expression of hepatic interferon-stimulated genes is
strongly associated with both treatment response and
genetic variation of IL28B [29]. In our study, we
assessed the impact of PEG-IFN/RBV on the gene
expression profiles in PBMCs of patients with CH-C
during treatment and analyzed these data according to
their IL28B genotype status as well as their SVR out-
come. We used previously collected gene expression
data from a cohort of CH-C patients who were under-
going treatment with PEG-IFN/RBV [19] and analyzed
the gene expression profile of these patients according
to these patients’ IL28B genotype status. Furthermore,
this gene expression analysis was coupled with pathway
analyses offering a novel approach to the interpretation
of gene expression data [26]. This approach provided us
with further advancement over previously published
time course studies of IFN-inducible genes in PBMCs of
HCV patients treated with PEG-IFN/RBV [30,31].
Our approach was validated by the fact that the most
commonly activated pathway in our analysis was the
Hepatitis C Pathway itself [Figure 1] Analysis of this
pathway revealed two interesting observations. First,
CH-C patients with IL28B T* genotype seem to have
baseline activation of the Hepatitis C Pathway, via the
increased expression of the IKBKE gene known to be
essential for regulating antiviral signaling, whereas the
CH-C patients with the IL28B C/C genotype showed
activation in this pathway only after the initiation of
treatment (Day 7). Second, we observed that IL28B C/C
genotype patients with CH-C maintained a sustained
involvement of this pathway throughout the entire 56
days of treatment with PEG-IFN/RBV; The IL28B T*
patients, on the other hand, showed activation at base-
line, with minimal involvement past day 7 after the
initiation of treatment (Table 3).
Our study also highlighted the Chemokine Signaling as
a pathway of interest. In fact, patients with CH-C IL28B
CC genotype showed a clear treatment induced involve-
ment of this pathway, whereas IL28B T* genotype failed
to show any treatment induced activation of this pathway
(Table 4).
It should be noted that IL28B polymorphisms has
not been as strongly associated with treatment out-
comes for patients with chronic hepatitis B or human
Table 4 Genes involved in the Cytokine Signaling
Pathway related genes are differentially regulated in
IL28B CC and IL28 T* genotypes over the course of the
treatment.
Genotype Day 0 Day 1 Day 7 Day 28 Day 56
IL28B CC (1)
IL1B
(0) (4)
ADAR
FYN
IRF3
STAT3
(5)
EIF2AK2
FAS
FYN
IRF3
IRF7
(3)
FYN
IRF3
MX1
IL28B T* (1)
IKBKE
(1)
TRAF6
(3)
FAS
IFNAR1
TRAF6
(1)
IFNAR1
(0)
Upregulated genes are shown in bold; Downregulated genes are shown in
regular font.
ĂƐĞůŝŶĞ ϮϰŚƌƐ ϳĚ ϮϴĚ ϱϲĚ
WфϬ͘ϬϮ WфϬ͘ϬϬϲ
Figure 3 The time course of the changes in SOCS1 expression
levels in patients who subsequently achieved or not achieved
SVR. Blue columns: patients who achieved SVR (N = 23). Red
columns: patients who not achieved SVR (N = 33).
ĂƐĞůŝŶĞ ϮϰŚƌƐ ϳĚ ϮϴĚ ϱϲĚ
WфϬ͘ϬϮ
Figure 4 T h et i m ec o u r s eo ft h ec h a n g e si nI R F 2e x p r e s s i o n
levels in patients who subsequently achieved or not achieved
SVR. Blue columns: patients who achieved SVR (N = 23). Red
columns: patients who not achieved SVR (N = 33).
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Page 7 of 10immunodeficiency virus to date [32,33]. However, it is
possible that HCV shares its regulatory pathways with
other types of viruses. In this context, our observation
that the pathway related to measles infection is espe-
cially intriguing [Figure 2]. In fact, it has been recently
shown that the V protein of the measles virus is a
potent inhibitor of IFN-lambda which is encoded by
the IL28B gene [34]. It may be interesting to assess
any potential association of IL28B and SVR in CH-C
patients according to their previous exposure to
measles virus or MMR vaccine.
To gain additional insights into the mechanisms of
genotype-specific treatment-failure, we compared the
lists of genes which were differentially expressed in
patients who could not achieve SVR, irrespective of
their Il28B genotype status. Remarkably, when gene
expression patterns were compared at baseline, IRF2
and SOCS1 genes were independently identified as
being down-regulated in all CH-C patients who failed
treatment, regardless of their IL28B genotypes. Interest-
ingly, transcriptional silencing of the SOCS1 gene in the
liver has been suggested as a potential reason for treat-
m e n tf a i l u r ei nC H - Cp a t i e n t sa sw e l la si nt h em o u s e
model of chronic HCV infection [35]. In both instances,
silencing of SOCS1 led to permanent activation of the
JAK-STAT signaling pathway [35]. Additionally, hepato-
cytes lacking SOCS-1 exhibit a prolonged response to
IFNg [36]. Conversely, when SOCS1 was over-expressed,
the propagation of the signal through hepatic inter-
feron-dependent pathways is abrogated [36,37]. In fact,
this interferon pathway shutdown also influences IFN-l
[37]. Our data collected using PBMCs indicate that the
action of SOCS1 is independent of IL28B genotype.
Furthermore, our data suggest that CH-C patients who
do not have the SOCS1 gene silenced have a better
chance of achieving SVR. This hypothesis is supported
by our previous observation that the lack of SOCS1 sup-
pression in PBMCs could serve as a predictor of SVR,
independent of the viral genotype or treatment status
[38].
This study has two major limitations, an enrollment of
patients infected by different HCV genotypes and of differ-
ent ethnicity and evaluation of peripheral blood samples
instead of hepatic tissue. However, it is important to note
that we carried out our gene expression pathway analyses
with all HCV genotypes and then analyzed the data sepa-
rately for HCV genotype 1 patients. This was done to
assess the impact of HCV genotype- specific response
according to IL28B alleles. Nevertheless, the results of our
pathway analyses for both HCV genotype groups were
very similar, confirming that IL28B acts independent of
HCV genotype.
Conclusions
In conclusion, the most striking difference between the
response patterns of IL28B C/C and T* genotypes to
antiviral treatment across all pathways, was the sus-
tained pattern of treatment-induced gene expression in
IL28B C/C patients. In the case of IL28 T* genotype,
the pre-activation of this pathway, the lack of sustained
activation post treatment or a combination of both,
could provide an explanation for their high rate of treat-
ment failure. Further studies are needed to clarify the
mechanism of IL28B genotyping and its impact on treat-
ment response.
Additional material
Additional file 1: The complete list of analyzed genes. This file lists all
genes analyzed using qRT-PCR and includes gene names, gene IDs and
the biological functions of these genes.
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